
Midatech Pharma plc MTP
Annual report 2025
added 04-11-2026
Midatech Pharma plc Operating Cycle 2011-2026 | MTP
Annual Operating Cycle Midatech Pharma plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | 245 | 3.37 K | - | - | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.37 K | 245 | 1.81 K |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
127 | - | - | $ 546 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
237 | $ 21.6 | 1.12 % | $ 1.01 B | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | ||
|
Clearside Biomedical
CLSD
|
61.7 | - | - | $ 25.3 M | ||
|
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Akebia Therapeutics
AKBA
|
210 | $ 1.54 | 4.76 % | $ 396 M | ||
|
Aquestive Therapeutics
AQST
|
223 | $ 4.16 | -0.72 % | $ 445 M | ||
|
Arcutis Biotherapeutics
ARQT
|
291 | $ 25.23 | 4.6 % | $ 3.21 B | ||
|
Chimerix
CMRX
|
588 | - | - | $ 756 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
321 | $ 33.31 | 2.19 % | $ 2.21 B | ||
|
Autolus Therapeutics plc
AUTL
|
129 | $ 1.5 | 2.04 % | $ 399 M | ||
|
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | ||
|
CTI BioPharma Corp.
CTIC
|
90.1 | - | - | $ 1.2 B |